Cartilage and joint tissue metabolic pathways

Cartilage and joint tissue metabolic pathways encompass the complex network of biochemical processes responsible for the synthesis, maintenance, and degradation of the extracellular matrix (ECM) within articular joints (PubMed: 25067118). These pathways are primarily regulated by chondrocytes, which balance the production of structural proteins like type II collagen and proteoglycans with the activity of catabolic enzymes such as matrix metalloproteinases (MMPs) and aggrecanases (StatPearls: NBK532957). In pathological conditions like osteoarthritis, these pathways become dysregulated, shifting toward a catabolic state characterized by ECM breakdown and chronic inflammation (NIH: PMC4284012). This metabolic imbalance is often driven by pro-inflammatory cytokines like IL-1β and TNF-α, which stimulate the expression of degradative enzymes (PubMed: 23951012). While these pathways contain numerous specific therapeutic targets, such as individual enzymes or cytokines, the term itself refers to a broad physiological system rather than a single druggable molecule (PubMed: 30172234). Therapeutic interventions often aim to restore metabolic homeostasis by either inhibiting degradative enzymes or stimulating anabolic repair mechanisms. Current research focuses on modulating signaling pathways like Wnt/β-catenin and TGF-β to promote chondrocyte health and tissue regeneration (PubMed: 29129517). Understanding these pathways is crucial for developing disease-modifying osteoarthritis drugs (DMOADs) that can halt or reverse joint degeneration.

Other names

Joint metabolismChondrocyte metabolic pathwaysExtracellular matrix metabolism

Modulation of anabolic and catabolic signaling within the joint environment to preserve extracellular matrix integrity.